DOP2014000173A - Fenilimidazopirazoles sustituidos y su uso - Google Patents

Fenilimidazopirazoles sustituidos y su uso

Info

Publication number
DOP2014000173A
DOP2014000173A DO2014000173A DO2014000173A DOP2014000173A DO P2014000173 A DOP2014000173 A DO P2014000173A DO 2014000173 A DO2014000173 A DO 2014000173A DO 2014000173 A DO2014000173 A DO 2014000173A DO P2014000173 A DOP2014000173 A DO P2014000173A
Authority
DO
Dominican Republic
Prior art keywords
diseases
phenylimidazopirazoles
replaced
prevention
preparation
Prior art date
Application number
DO2014000173A
Other languages
English (en)
Spanish (es)
Inventor
Bernd Buchmann
Mario Lobell
Antje Kahnert
Joachim Telser
Niels Lindner
Klemens Lustig
Sylvia Grünewald
Frank Sübmeier
Hannah Jöriben
Michael Härter
Mélanie Héroult
Original Assignee
Bayer Pharma AG
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47594775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2014000173(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG, Bayer Ip Gmbh filed Critical Bayer Pharma AG
Publication of DOP2014000173A publication Critical patent/DOP2014000173A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DO2014000173A 2012-01-25 2014-07-24 Fenilimidazopirazoles sustituidos y su uso DOP2014000173A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12152515 2012-01-25

Publications (1)

Publication Number Publication Date
DOP2014000173A true DOP2014000173A (es) 2014-08-31

Family

ID=47594775

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2014000173A DOP2014000173A (es) 2012-01-25 2014-07-24 Fenilimidazopirazoles sustituidos y su uso

Country Status (30)

Country Link
US (2) US20150005288A1 (enExample)
EP (1) EP2807162B1 (enExample)
JP (1) JP6101290B2 (enExample)
KR (1) KR20140117582A (enExample)
CN (1) CN104411707B (enExample)
AP (1) AP2014007869A0 (enExample)
AR (1) AR089788A1 (enExample)
AU (1) AU2013211707A1 (enExample)
BR (1) BR112014018450A8 (enExample)
CA (1) CA2862163A1 (enExample)
CL (1) CL2014001959A1 (enExample)
CO (1) CO7101244A2 (enExample)
CR (1) CR20140362A (enExample)
CU (1) CU20140096A7 (enExample)
DO (1) DOP2014000173A (enExample)
EA (1) EA201491427A1 (enExample)
EC (1) ECSP14010868A (enExample)
ES (1) ES2639338T3 (enExample)
GT (1) GT201400161A (enExample)
IL (1) IL233652A0 (enExample)
MA (1) MA35877B1 (enExample)
MX (1) MX2014008893A (enExample)
PE (1) PE20142421A1 (enExample)
PH (1) PH12014501687A1 (enExample)
SG (1) SG11201404118XA (enExample)
TN (1) TN2014000320A1 (enExample)
TW (1) TW201343649A (enExample)
UY (1) UY34590A (enExample)
WO (1) WO2013110590A1 (enExample)
ZA (1) ZA201405392B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2862163A1 (en) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituted phenylimidazopyrazoles and use thereof
CA3280124A1 (en) 2013-07-31 2025-10-31 Avalyn Pharma Inc. Aerosol imatinib compounds and uses thereof
US20180368404A1 (en) 2014-11-06 2018-12-27 Basf Se 3-pyridyl heterobicyclic compound for controlling invertebrate pests
BR112018007034B1 (pt) * 2015-10-08 2022-10-11 Fmc Corporation Composto, composição, método para controlar uma praga de invertebrados e semente revestida
PY1974629A (es) * 2018-09-13 2021-01-11 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
CN109096195A (zh) * 2018-09-27 2018-12-28 上海雅本化学有限公司 一种艾曲波帕的制备方法
KR20220082835A (ko) * 2019-10-16 2022-06-17 바이엘 악티엔게젤샤프트 1,1'-디술판디일비스(4-플루오로-2-메틸-5-니트로벤졸)의 제조 방법
BR112022015110A2 (pt) * 2020-01-29 2022-11-08 Foghorn Therapeutics Inc Compostos e usos dos mesmos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0753730B2 (ja) * 1988-07-26 1995-06-07 三共株式会社 イミダゾピラゾール誘導体
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
KR101061599B1 (ko) * 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
CA2765534C (en) * 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)
KR101116756B1 (ko) * 2009-10-27 2012-03-13 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 신규의 1,6-치환된 인돌 화합물
CA2862163A1 (en) * 2012-01-25 2013-08-01 Bayer Pharma Aktiengesellschaft Substituted phenylimidazopyrazoles and use thereof

Also Published As

Publication number Publication date
WO2013110590A1 (de) 2013-08-01
GT201400161A (es) 2015-03-05
IL233652A0 (en) 2014-08-31
SG11201404118XA (en) 2014-10-30
ZA201405392B (en) 2015-12-23
US20130190290A1 (en) 2013-07-25
EP2807162B1 (de) 2017-06-07
ECSP14010868A (es) 2015-12-31
CA2862163A1 (en) 2013-08-01
EA201491427A1 (ru) 2015-01-30
TN2014000320A1 (en) 2015-12-21
US20150005288A1 (en) 2015-01-01
UY34590A (es) 2013-09-02
CL2014001959A1 (es) 2014-11-07
CR20140362A (es) 2014-08-21
TW201343649A (zh) 2013-11-01
MA35877B1 (fr) 2014-12-01
EP2807162A1 (de) 2014-12-03
BR112014018450A8 (pt) 2017-07-11
AU2013211707A1 (en) 2014-08-07
PE20142421A1 (es) 2015-01-11
CU20140096A7 (es) 2015-02-26
JP6101290B2 (ja) 2017-03-22
KR20140117582A (ko) 2014-10-07
PH12014501687A1 (en) 2014-10-20
CO7101244A2 (es) 2014-10-31
AP2014007869A0 (en) 2014-08-31
US9394309B2 (en) 2016-07-19
BR112014018450A2 (enExample) 2017-06-20
HK1203198A1 (en) 2015-10-23
MX2014008893A (es) 2014-08-26
JP2015504904A (ja) 2015-02-16
CN104411707A (zh) 2015-03-11
CN104411707B (zh) 2017-03-01
AR089788A1 (es) 2014-09-17
ES2639338T3 (es) 2017-10-26

Similar Documents

Publication Publication Date Title
CU20140096A7 (es) Fenilimidazopirazoles sustituidos y su uso
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2019010601A (es) Terapia de combinacion para tratar cancer.
NZ720736A (en) Antibody drug conjugates (adcs) with kinesin spindel protein (ksp)
MX373187B (es) Terapia de combinación para tratar cáncer.
BR112018001640A2 (pt) combinação de antagonista da pd-1 com um inibidor de egfr
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
DOP2016000150A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos
IL239488A0 (en) A gpc3-targeted medicinal agent for the treatment of patients for whom treatment with a gpc3-targeted medicinal agent is beneficial
UY35115A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
CR20120596A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
UY35652A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
UY32237A (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
BR112014031088A8 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
CR20140513A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
MX373851B (es) Métodos de administración de tratamiento con pirfenidona.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
MX380565B (es) Terapias combinadas de coenzima q10 para el tratamiento de cáncer.
DOP2012000284A (es) Heterociclilbencilpirazoles sustituidos y uso de los mismos
BR112015006363A2 (pt) combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
UY36408A (es) Derivados de pirido benzodiazepina sustituidos y su utilización
BR112015011099A2 (pt) Composições e métodos para o tratamento de diplasia ectodérmica
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".